OrthoPediatrics Corp. (KIDS) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
KIDS Revenue Growth
Revenue Breakdown (FY 2025)
KIDS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
KIDS Revenue Analysis (2014–2025)
As of May 8, 2026, OrthoPediatrics Corp. (KIDS) generated trailing twelve-month (TTM) revenue of $243.3 million, reflecting strong growth of +13.3% year-over-year. The most recent quarter (Q1 2026) recorded $59.4 million in revenue, down 3.6% sequentially.
Looking at the longer-term picture, KIDS's 5-year compound annual growth rate (CAGR) stands at +27.2%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $236.3 million in 2025, representing a new all-time high.
Revenue diversification analysis shows KIDS's business is primarily driven by Trauma and Deformity (70%), Spine (28%), and Sports Medicine And Other (2%). With over half of revenue concentrated in Trauma and Deformity, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ATEC (-7.4% YoY), XTNT (+16.9% YoY), and GMED (+23.5% YoY), KIDS has underperformed the peer group in terms of revenue growth. Compare KIDS vs ATEC →
KIDS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| KIDSCurrent | $243M | +13.3% | +27.2% | -12.3% | |
 ATEC | $764M | -7.4% | +39.5% | -10.7% | |
 XTNT | $117M | +16.9% | +12.6% | -10.3% | |
 GMED | $2.9B | +23.5% | +30.1% | 16.3% | |
 ZBH | $8.2B | +9.2% | +6.1% | 16.5% | |
 SYK | $25.1B | +11.2% | +11.8% | 19.5% |
KIDS Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $236.3M | +15.4% | $172.7M | 73.1% | $-28,999,000 | -12.3% |
| 2024 | $204.7M | +37.6% | $148.6M | 72.6% | $-29,521,000 | -14.4% |
| 2023 | $148.7M | +21.6% | $111.3M | 74.8% | $-26,751,000 | -18.0% |
| 2022 | $122.3M | +24.7% | $90.7M | 74.1% | $-25,399,000 | -20.8% |
| 2021 | $98.0M | +37.9% | $73.4M | 74.9% | $-18,024,000 | -18.4% |
| 2020 | $71.1M | -2.0% | $55.0M | 77.4% | $-26,755,000 | -37.6% |
| 2019 | $72.6M | +26.0% | $54.6M | 75.3% | $-9,077,000 | -12.5% |
| 2018 | $57.6M | +26.2% | $42.7M | 74.2% | $-9,553,000 | -16.6% |
| 2017 | $45.6M | +22.3% | $34.5M | 75.5% | $-6,472,000 | -14.2% |
| 2016 | $37.3M | +20.3% | $26.4M | 70.7% | $-6,127,000 | -16.4% |
See KIDS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KIDS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KIDS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKIDS — Frequently Asked Questions
Quick answers to the most common questions about buying KIDS stock.
Is KIDS's revenue growth accelerating or slowing?
KIDS maintains +13.3% revenue growth, in line with its 5-year CAGR of +27.2%. TTM revenue stands at $243M. Growth rate remains consistent with historical average.
What is KIDS's long-term revenue growth rate?
OrthoPediatrics Corp.'s 5-year revenue CAGR of +27.2% reflects the sustained expansion pattern. Current YoY growth of +13.3% is near this long-term average.
How is KIDS's revenue distributed by segment?
KIDS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.